Clinical Trials Logo

Kidney Neoplasms clinical trials

View clinical trials related to Kidney Neoplasms.

Filter by:

NCT ID: NCT00003133 Completed - Bladder Cancer Clinical Trials

Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer

Start date: September 1997
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy following surgery in treating patients with advanced bladder cancer.

NCT ID: NCT00003126 Completed - Kidney Cancer Clinical Trials

Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer

Start date: June 1997
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy of post-operative high-dose bolus interleukin-2 (IL-2) in patients with high-risk renal cell carcinoma (RCC).

NCT ID: NCT00003105 Completed - Bladder Cancer Clinical Trials

Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer

Start date: September 1997
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy in treating patients with metastatic or locally advanced bladder cancer.

NCT ID: NCT00003102 Completed - Kidney Cancer Clinical Trials

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

Start date: November 17, 1998
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in treating patients with advanced kidney cancer.

NCT ID: NCT00003091 Completed - Kidney Cancer Clinical Trials

High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma

Start date: January 1996
Phase: Phase 2
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer or melanoma cells. PURPOSE: Phase II trial to study the effectiveness of high-dose interferon alfa and interleukin-2 in treating patients with metastatic kidney cancer or melanoma.

NCT ID: NCT00002914 Completed - Bladder Cancer Clinical Trials

Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract

Start date: July 15, 1997
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of piritrexim in treating patients with advanced cancer of the urinary tract that has not responded to previous treatment.

NCT ID: NCT00002847 Active, not recruiting - Kidney Cancer Clinical Trials

Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Start date: September 1995
Phase: Phase 2
Study type: Interventional

RATIONALE: Biological therapies use different ways to stimulate the immune system to try to stop cancer cells from growing. Combining interferon alfa and interleukin-2 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa and interleukin-2 in treating patients with metastatic kidney cancer.

NCT ID: NCT00002846 Active, not recruiting - Kidney Cancer Clinical Trials

Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer

Start date: September 1995
Phase: Phase 2
Study type: Interventional

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase II trial to study the effectiveness of low-dose interleukin-2 in treating patients with metastatic or recurrent kidney cancer.

NCT ID: NCT00002737 Completed - Kidney Cancer Clinical Trials

Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer

Start date: March 1996
Phase: Phase 3
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of the cancer cells and slow the growth of kidney cancer. Isotretinoin may help kidney cancer cells develop into normal cells. It is not yet known whether interferon alfa plus isotretinoin is more effective than interferon alfa alone for kidney cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without isotretinoin in treating patients who have metastatic kidney cancer.

NCT ID: NCT00002611 Completed - Kidney Cancer Clinical Trials

Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer

Start date: July 1995
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. It is not yet known whether combination chemotherapy alone or combination chemotherapy plus radiation therapy is more effective for childhood kidney cancer. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy with or without radiation therapy in treating children who have kidney cancer.